PMS2 and cancer: In the integrated germline and somatic assessment presented here, germline variants in MSH6 and PMS2 were assessed with the combination of MMR/MSI/IHC/LOH and personal clinical findings, all of which collectively elucidate a likely involvement of the germline variant in patient cancer.